Renewed interest in vancomycin, resulting from the increase in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis, has prompted new investigations regarding the pharmacokinetics, potential for toxicity, and dosage adjustment guidelines of vancormycin (8, 9, 11, 16, 17, 21) . Altered pharmacokinetics of vancomycin resulting in increased dosage requirements have been investigated in. burn patients. Although there is clinical evidence for increased vancomycin dosage requirements in this patient population, data supporting these observations have been inconclusive (3, 6) . A similar phenomenon has been documented to occur with aminoglycoside administration'in burn patients. The mechanism for enhanced aminoglycoside elimination that results in increased dosage requirements'for burn patients appears to be related to an increased glomerular filtration rate (12, (23) (24) (25) . Intravenous drug abusers (IVDA) have also been reported to eliminate aminoglycosides at a rate which necessitates more aggressive aminoglycoside dosage regimens (10) . This observation has not been reported with vancomycin' a'dministration in this patient population. In this inve'stigation, we compared the steadystate pharmacokinetics of vancomycin in burn patients, IVDA, 'and a control population.
MATERIALS AND METHODS
A total of 34 patients participated in this study. Ages ranged from 18 to 64 years (mean ± standard deviation, 37 10.9 years). Ten burn patients (5 collected over the dosing interval by spontaneous voiding. One of the investigators was present in the subject's room for the majority of the collection period. Serum and urine samples were stored at -20°C until analysis. Samples were assayed for vancomycin content within 1 week from the time of collection by a fluorescence polarization immunoassay (TDx; Diagnostic Division, Abbott Laboratories, Irving, Tex.). Our intra-and interrun coefficients of variation were less than 6% in the concentration range of 0.6 to 100 ,ug/ml. The coefficients of variation for the control standards that were run with each group of subject specimens averaged 4.7% for the high control (75 ,ug/ml), 1.8% for the medium control (35 ,ug/ml), and 3.5% for the low control (7.0 ,ug/ml).
Vancomycin serum protein binding was determined by ultrafiltration of the 1-, 6-, and 11-h serum samples. Total vancomycin and unbound vancomycin concentrations were determined in serum with a micropartition system (MPS-1; Amicon Corp., Danvers, Mass.). The free fraction (fu) of vancomycin was expressed as the ratio of the vancomycin concentration in the ultrafiltrate to that in serum multiplied by 100. Minimum vancomycin absorption (mean + SD recovery, 97.2% + 0.8%) was observed when an ultrafiltrate of serum was spiked (24 eg/ml) with vancomycin (five replicates). This observation is consistent with those in previous reports using this method for the determination of vancomycin serum protein binding (1, 16).
The serum concentration-versus-time data were fit to polyexponential functions with a nonlinear least-squares regression program (4) . The minimum number of exponentials needed to describe the curve was determined with a modified Akaike Information Criteria test with a weighting factor of l/y2 (4). The area under the serum concentrationversus-time curve over the dosing interval (AUCSSOT ) was calculated by the linear trapezoidal rule with the LAGRAN program (15) . Total body clearance (CL) was calculated as follows: CL = dose/AUCSS-r
The steady-state volume of distribution (Vss) was calculated with the formula of Gibaldi and Perrier (7) The CLR/CLF ratio was calculated to elucidate the mechanisms of vancomycin renal excretion.
Differences in patient characteristics and pharmacokinetic parameters for the three groups were determined by analysis of variance. Tukey's test was used to identify differences between burn patients, IVDA, and controls. Differences between trough (i.e., the sample prior to dosing) vancomycin concentrations and C (i.e., the last sample) were compared with a paired Studnt t test to ascertain that patients had indeed reached the steady state. Statistical significance was defined as P < 0.05. Data are presented as means ± SDs unless otherwise indicated.
RESULTS
The demographic characteristics, including burn patient descriptions, are shown in Table 1 . Infection diagnosis consisted of sepsis (burn, n = 10; IVDA, n = 3; control, n = 5), cellulitis (IVDA, n = 6; control, n = 4), osteomyelitis (IVDA, n = 3; control, n = 1), septic arthritis (IVDA, n = 1), and endocarditis (IVDA, n = 1). The time postburn in which patients in the burn group were started on vancomycin therapy ranged from 7 to 45 days. There were no significant differences among groups in age, actual body weight, or serum creatinine. Overall, serum albumin levels were low in all three groups, ranging from 1.0 to 3.8 mg/dl (all groups combined, 2.4 + 0.7 mg/dl) but were significantly lower in the burn patients (1.7 ± 0.5 mg/dl). Burn patients tended to be more aggressively dosed initially, accounting for the significant difference between vancomycin dosages prescribed for burn and nonburn patients. There were no significant differences between Cmin and trough vancomycin concentrations in serum, indicating the achievement of the steady state.
Mean values for steady-state vancomycin pharmacokinetic parameters are shown in Table 2 There are conflicting data in the literature as to the ability of CLCR to predict vancomycin CL in various patient populations. While we observed a reasonable correlation (all three patient groups combined) between CLCR and vancomycin CL (r2 = 0.77), the limited range of CLCR values in our patient population (which excluded those with renal dysfunction) did not permit us to make a rigorous assessment of the utility of CLCR in guiding dosage regimen design.
In summary, burn patients exhibit a higher vancomycin CL than do nonburn patients and, therefore, require more frequent and higher doses. The mechanism of this enhanced clearance appears to be through both increased filtration and increased secretory clearance. A similar mechanism may be responsible for the apparently higher vancomycin CL seen in the IVDA group; however, we were unable to demonstrate a statistically significant change. Therefore, this observation requires confirmation in a larger IVDA population before specific dosage recommendations can be made. Until more information is available, it would seem prudent to monitor this patient population closely, anticipating that IVDA may require more aggressive vancomycin dosing.
